B cell alterations during BAFF inhibition with belimumab in SLE

Name: B cell alterations during BAFF inhibition with belimumab in SLE
Creator: Daniel Ramsköld
Published: 2018-12-29T14:40:50.444Z
Keywords: Immunology, Rheumatology

Ramsköld, Daniel; Parodis, Ioannis; Tadepally,  Lakshmikanth; Sippl, Natalie; Chen, Yang; Zickert, Agneta; Mikeš, Jaromír; Achour, Adnane; Amara, Khaled; Brodin, Petter; Gunnarsson, Iva; Malmström, Vivianne

doi:10.17632/7894wb6yxh.1

B cell alterations during BAFF inhibition with belimumab in SLE

Published: 29 December 2018| Version 1 | DOI: 10.17632/7894wb6yxh.1

Contributors:

Daniel Ramsköld,

,

Description

Mass cytometry data, systemic lupus erythematosus patients at Karolinska Universitetssjukhuset at the start of belimumab treatment and follow-up time-points. Generated on a CyTOF2 machine. In run1, B cells were gated for CD20 (positive) and CD3 (negative) and CD4 T cells for CD20 (negative), CD3 (positive) and CD4 (positive). The data for both runs has been bead normalised.

Files

Institutions

Karolinska Institutet, Karolinska Universitetssjukhuset, Karolinska Institutet Department of Medicine Solna

B cell alterations during BAFF inhibition with belimumab in SLE

Description

Files

Institutions

Categories

Licence